<DOC>
	<DOCNO>NCT00003407</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Chemoprotective drug , amifostine , may protect normal cell side effect chemotherapy . PURPOSE : Phase II trial study effectiveness amifostine high-dose combination chemotherapy treat patient acute myeloid leukemia chronic myelogenous leukemia .</brief_summary>
	<brief_title>Amifostine High-Dose Combination Chemotherapy Treating Patients With Acute Myeloid Leukemia Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I. Assess effect amifostine response remission induction therapy consolidation cytarabine mitoxantrone patient poor prognosis acute myeloid leukemia ( AML ) , relapse AML , blastic phase chronic myelogenous leukemia ( CML ) . II . Assess effect amifostine biology AML CML cell vivo patient population . OUTLINE : Patients receive treatment prior induction therapy protocols CYL 90-03 CYL 97-59 . Induction therapy consist amifostine IV day 1 5 three time week day 6 28 . Fifteen minute amifostine day 1 5 , patient receive cytarabine IV 3 hour hour 0 hour 12 mitoxantrone IV 1 hour hour 15 . Patients enter remission receive second course induction therapy . Patients persistent AML follow second course remove study . Patients achieve complete response ( CR ) , clinical CR , remission bone marrow without hematologic recovery return myelodysplastic syndrome receive consolidation therapy . Consolidation therapy consist amifostine IV day 1 5 three time week blood count recover day 30 , whichever come first . Patients also receive cytarabine mitoxantrone induction therapy . Patients receive second course consolidation therapy begin 1 week blood count recover . After completion consolidation therapy , patient enrol protocol MDS 97-53 . PROJECTED ACCRUAL : A maximum 50 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose high risk acute myeloid leukemia ( AML ) define : AML myelodysplastic syndrome ; refractory anemia excess blast transformation `` AML evolution '' also eligible AML follow chronic myeloproliferative disorder ( except chronic myelogenous leukemia ) Therapy relate AML AML follow exposure know hematopoietic toxin Relapsed AML Age 70 old OR AML first relapse define : AML first relapse without treatment protocol AML9801 Relapsed follow standard chemotherapy Previously treat AML9701 relapse least 6 month remission OR Chronic myelogenous leukemia ( CML ) blast crisis define : 20 % blast cell bone marrow peripheral blood Pure lymphoid blastic crisis eligible resistant acute lymphocytic leukemia type treatment regimen relapse initial response treatment PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 3 mg/dL SGOT/SGPT great 2.5 time upper limit normal Renal : Creatinine le 3 mg/dL Cardiovascular : No overt congestive heart failure uncontrollable ventricular arrhythmia No uncontrollable hypertension Neurologic : No cerebellar dysfunction Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>neutropenia</keyword>
</DOC>